假说：血管紧张素转换酶抑制剂和血管紧张素受体阻滞剂可能会增加 COVID-19 重症风险。
Hypothesis: angiotensin-converting enzyme inhibitors and angiotensin receptor blockers may increase the risk of severe COVID-19.
机构信息
Environmental and Occupational Health Sciences, School of Public Health; Professor of Anesthesiology, School of Medicine, Louisiana State University Health Sciences Center, 2020 Gravier Street New Orleans, Louisiana 70112 USA.
出版信息
J Travel Med. 2020 May 18;27(3). doi: 10.1093/jtm/taaa041.
Abstract
Intravenous infusions of angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) in experimental animals increase the numbers of angiotensin-converting enzyme 2 (ACE2) receptors in the cardiopulmonary circulation. ACE2 receptors serve as binding sites for SARS-CoV-2 virions in the lungs. Patients who take ACEIs and ARBS may be at increased risk of severe disease outcomes due to SARS-CoV-2 infections.
摘要
在实验动物中静脉输注血管紧张素转换酶抑制剂（ACEIs）和血管紧张素受体阻滞剂（ARBs）会增加心肺循环中血管紧张素转换酶 2（ACE2）受体的数量。ACE2 受体是肺部 SARS-CoV-2 病毒颗粒的结合位点。服用 ACEIs 和 ARBs 的患者可能由于 SARS-CoV-2 感染而面临更严重疾病后果的风险增加。
相似文献
1
Hypothesis: angiotensin-converting enzyme inhibitors and angiotensin receptor blockers may increase the risk of severe COVID-19.假说：血管紧张素转换酶抑制剂和血管紧张素受体阻滞剂可能会增加 COVID-19 重症风险。
J Travel Med. 2020 May 18;27(3). doi: 10.1093/jtm/taaa041.
2
A Meta-analysis of the Relationship Between Renin-Angiotensin-Aldosterone System Inhibitors and COVID-19.肾素-血管紧张素-醛固酮系统抑制剂与新型冠状病毒肺炎关系的Meta分析
Am J Cardiol. 2020 Sep 1;130:159-161. doi: 10.1016/j.amjcard.2020.05.038. Epub 2020 Jun 2.
3
COVID-19 and Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers: What Is the Evidence?新型冠状病毒肺炎与血管紧张素转换酶抑制剂及血管紧张素受体阻滞剂：证据是什么？
JAMA. 2020 May 12;323(18):1769-1770. doi: 10.1001/jama.2020.4812.
4
COVID-19: The heart of the issue.新冠病毒：问题的核心。
J Card Surg. 2020 Aug;35(8):2112. doi: 10.1111/jocs.14684. Epub 2020 Jun 16.
5
Cardiovascular disease and the impact of COVID-19.心血管疾病与2019冠状病毒病的影响
J Card Surg. 2020 Aug;35(8):2113. doi: 10.1111/jocs.14682. Epub 2020 Jun 16.
6
COVID-19 and cardiovascular disease: What we know, what we think we know, and what we need to know.2019冠状病毒病与心血管疾病：我们已知的、我们自认为已知的以及我们需要了解的情况。
J Mol Cell Cardiol. 2020 Jul;144:12-14. doi: 10.1016/j.yjmcc.2020.04.026. Epub 2020 Apr 24.
7
8
Coronavirus Disease 2019 (COVID-19): Do Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers Have a Biphasic Effect?2019冠状病毒病（COVID-19）：血管紧张素转换酶抑制剂/血管紧张素受体阻滞剂是否具有双相效应？
J Am Heart Assoc. 2020 Apr 7;9(7):e016509. doi: 10.1161/JAHA.120.016509. Epub 2020 Apr 1.
9
Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers may be harmful in patients with diabetes during COVID-19 pandemic.在新冠疫情期间，血管紧张素转换酶抑制剂和血管紧张素受体阻滞剂可能对糖尿病患者有害。
Diabetes Metab Syndr. 2020 Jul-Aug;14(4):349-350. doi: 10.1016/j.dsx.2020.04.019. Epub 2020 Apr 15.
10
Facts and reflections on COVID-19 and anti-hypertensives drugs.关于新冠病毒肺炎与抗高血压药物的事实与思考。
Drug Discov Ther. 2020 May 6;14(2):105-106. doi: 10.5582/ddt.2020.01017. Epub 2020 Mar 26.
引用本文的文献
1
Angiotensin-Converting Enzyme Inhibition and/or Angiotensin Receptor Blockade Modulate Cytokine Profiles and Improve Clinical Outcomes in Experimental COVID-19 Infection.血管紧张素转换酶抑制和/或血管紧张素受体阻断调节细胞因子谱并改善实验性 COVID-19 感染的临床结局。
Int J Mol Sci. 2025 Aug 8;26(16):7663. doi: 10.3390/ijms26167663.
2
Therapeutic Approaches for COVID-19: A Review of Antiviral Treatments, Immunotherapies, and Emerging Interventions.2019冠状病毒病的治疗方法：抗病毒治疗、免疫疗法及新兴干预措施综述
Adv Ther. 2025 May 8. doi: 10.1007/s12325-025-03218-3.
3
Unveiling the Interplay-Vitamin D and ACE-2 Molecular Interactions in Mitigating Complications and Deaths from SARS-CoV-2.揭示维生素D与血管紧张素转换酶2（ACE-2）的分子相互作用在减轻新冠病毒（SARS-CoV-2）并发症和死亡方面的作用
Biology (Basel). 2024 Oct 16;13(10):831. doi: 10.3390/biology13100831.
4
Lisinopril increases lung ACE2 levels and SARS-CoV-2 viral load and decreases inflammation but not disease severity in experimental COVID-19.在实验性新冠肺炎中，赖诺普利可提高肺部血管紧张素转换酶2（ACE2）水平和严重急性呼吸综合征冠状病毒2（SARS-CoV-2）病毒载量，并减轻炎症，但不会降低疾病严重程度。
Front Pharmacol. 2024 Jul 12;15:1414406. doi: 10.3389/fphar.2024.1414406. eCollection 2024.
5
A Focus on the Pathophysiology of Adrenomedullin Expression: Endothelitis and Organ Damage in Severe Viral and Bacterial Infections.关注肾上腺髓质素表达的病理生理学：严重病毒和细菌感染中的血管内皮炎症和器官损伤。
Cells. 2024 May 22;13(11):892. doi: 10.3390/cells13110892.
6
Role of renin-angiotensin system/angiotensin converting enzyme-2 mechanism and enhanced COVID-19 susceptibility in type 2 diabetes mellitus.肾素-血管紧张素系统/血管紧张素转换酶2机制在2型糖尿病中增强新型冠状病毒肺炎易感性的作用
World J Diabetes. 2024 Apr 15;15(4):606-622. doi: 10.4239/wjd.v15.i4.606.
7
A comprehensive review on pharmacologic agents, immunotherapies and supportive therapeutics for COVID-19.关于COVID-19的药物制剂、免疫疗法和支持性疗法的全面综述。
Narra J. 2022 Dec;2(3):e92. doi: 10.52225/narra.v2i3.92. Epub 2022 Dec 8.
8
Pathological Interplay and Clinical Complications between COVID-19 and Cardiovascular Diseases: An Overview in 2023.2023年新型冠状病毒肺炎与心血管疾病之间的病理相互作用及临床并发症概述
Cardiology. 2024;149(1):60-70. doi: 10.1159/000533359. Epub 2023 Aug 16.
9
COVID-19-Triggered Acute Liver Failure and Rhabdomyolysis: A Case Report and Review of the Literature.COVID-19 引发的急性肝衰竭和横纹肌溶解症：病例报告及文献复习。
Viruses. 2023 Jun 27;15(7):1445. doi: 10.3390/v15071445.
10
Potential Drugs in COVID-19 Management.新冠病毒管理中的潜在药物。
Curr Med Chem. 2024;31(22):3245-3264. doi: 10.2174/0929867331666230717154101.
Zotero 插件